+

WO1999053945A8 - Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration - Google Patents

Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Info

Publication number
WO1999053945A8
WO1999053945A8 PCT/CA1999/000304 CA9900304W WO9953945A8 WO 1999053945 A8 WO1999053945 A8 WO 1999053945A8 CA 9900304 W CA9900304 W CA 9900304W WO 9953945 A8 WO9953945 A8 WO 9953945A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
growth inhibitory
axon regeneration
derivatives
neuron growth
Prior art date
Application number
PCT/CA1999/000304
Other languages
French (fr)
Other versions
WO1999053945A1 (en
Inventor
Samuel David
Lisa Joan Mckerracher
Peter Erich Braun
Original Assignee
Samuel David
Lisa Joan Mckerracher
Peter Erich Braun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel David, Lisa Joan Mckerracher, Peter Erich Braun filed Critical Samuel David
Priority to AU31347/99A priority Critical patent/AU3134799A/en
Publication of WO1999053945A1 publication Critical patent/WO1999053945A1/en
Publication of WO1999053945A8 publication Critical patent/WO1999053945A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

This invention pertains to compositions comprising immunogenic agents having neuron growth inhibitory properties, which cause polyreactive antibodies to be generated that bind to axon growth inhibitors, thereby promoting axon regeneration. Exemplary agents include myelin-associated glycoprotein (MAG), arretin or proteoglycan proteins. These compositions can be used to restore nerve transmission, particularly motor and sensory function, after spinal cord lesions or optic nerve damage. They can also be used to treat diseases involving axonal damage, such as Multiple Sclerosis and stroke. These compositions can be used further as prophylactic vaccines prior to onset of CNS disease or injury.
PCT/CA1999/000304 1998-04-16 1999-04-16 Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration WO1999053945A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU31347/99A AU3134799A (en) 1998-04-16 1999-04-16 Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,234,921 1998-04-16
CA2234921 1998-04-16

Publications (2)

Publication Number Publication Date
WO1999053945A1 WO1999053945A1 (en) 1999-10-28
WO1999053945A8 true WO1999053945A8 (en) 2000-03-02

Family

ID=4162334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000304 WO1999053945A1 (en) 1998-04-16 1999-04-16 Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration

Country Status (2)

Country Link
AU (1) AU3134799A (en)
WO (1) WO1999053945A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
CN100354307C (en) 2000-01-12 2007-12-12 耶鲁大学 NOGO receptor-mediated blockade of axonal growth
AUPQ614200A0 (en) * 2000-03-10 2000-03-30 Department Of Human Physiology, Flinders University School Of Medicine Method for treating chronic spinal cord injury
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
CA2607668A1 (en) 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191326535A (en) * 1913-11-19 1914-04-23 Charles Jules Henri Nicolle Improvements in and relating to Vaccines, Cultures and the like and the Preparation thereof.
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
WO1997007810A1 (en) * 1995-08-25 1997-03-06 The John Hopkins University School Of Medicine Compounds for stimulating nerve growth
CA2190418A1 (en) * 1996-11-15 1998-05-15 Zhi-Cheng Xiao Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof

Also Published As

Publication number Publication date
WO1999053945A1 (en) 1999-10-28
AU3134799A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
TW264480B (en)
WO1996004378A3 (en) Chimeric proteins and muteins of tissue factor pathway inhibitors tfpi and tfpi-2
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP2305822A3 (en) Methods and compositions for diseases associated with Amyloidosis
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2002029059A3 (en) Nogo receptor homologs
WO2001001748A3 (en) Peptide compounds that bind her2
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
WO2003030934A3 (en) Cpg formulations and related methods
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO1999041383A8 (en) Antigen library immunization
WO2004110360A3 (en) Proteoglycan degrading mutants for treatment of cns
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
EP1195161A3 (en) Anti-IgE vaccines
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO1999053945A8 (en) Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2002036614A3 (en) Peptides for use in the treatment of alzheimer's disease
WO1999059617A3 (en) Immunoregulator
WO2000012045A3 (en) Method for treating neurodegenerative disorders
WO2003001968A8 (en) Compositions and methods for inhibiting platelet activation and thrombosis
WO2001060990A3 (en) Sphingosine kinases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B8

Designated state(s): AE

AL Designated countries for regional patents

Kind code of ref document: B8

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 43/99 UNDER (54) THE TITLE IN ENGLISH SHOULD READ "NEURON GROWTH INHIBITORY MOLECULES OR DERIVATIVES THEREOF USED TO IMMUNIZE MAMMALS THEREBY PROMOTING AXON REGENERATION"

NENP Non-entry into the national phase in:

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载